Am J Transplant, Volume 18, Suppl 3 Archives - Page 5 of 211 - ATC Abstracts

2018 American Transplant Congress
Longitudinal Molecular Assessment of Renal Allograft and Short-Term Outcome: Markers of Injury and Recovery
S. Bontha,¹ A. Fernandez,¹ E. Bardhi,¹ L. Gallon,² V. Mas,¹ D. Maluf.¹
¹Surgery, UVA, Charlottesville; ²NWU, Chicago.
Background: Ischemia reperfusion (I/R) is influenced by both donor and recipient characteristics and affects early graft function and the recovery process. To understand underlying mechanisms…
2018 American Transplant Congress
Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients is Associated with Prolonged Cold Ischemic Time of Seropositive Donor Organs
C. Falk,^1,7 F. Schlott,^2,7 K. Katsrintaki,^1,7 D. Steubl,³ W. Puppe,⁴ C. Blume,⁵ H. Haller,⁶ L. Renders,³ U. Heemann,³ D. Busch,² M. Neuenhahn.^2,7
¹Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany; ²Institute for Medical Microbiology, Immunology and Hygiene, Technical University Munich, Munich, Germany; ³Department of Nephrology, Technical University Munich, Munich, Germany; ⁴Institute of Virology, Hannover Medical School, Hannover, Germany; ⁵Institute of Technical Chemistry, Leibniz University Hannover, Hannover, Germany; ⁶Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; ⁷DZIF TTU-IICH, DZIF, Hannover / Munich, Germany.
Introduction: Human Cytomegalovirus (CMV) infection is still a major risk factor for immunocompromised patients, e.g. kidney recipients. Based on the CMV serostatus of donor (D)…
2018 American Transplant Congress
Circulating Wnt Pathway Factors Are Non-Invasive Biomarkers of Transplant Vascular Injury
M. Seifert,¹ A. Malone,² L. Boohaker,¹ J. Gaut,² S. Jain,² D. Brennan,^2,3 R. Mannon.¹
¹UAB School of Medicine, Birmingham; ²Washington University, St. Louis; ³Johns Hopkins University, Baltimore.
Purpose: Transplant vascular injury (TVI) is a major cause of renal allograft failure and is resistant to treatment. Non-invasive pathogenic biomarkers of TVI would provide…
2018 American Transplant Congress
What's Normal? An Evaluation of Pediatric T Cell Markers in Healthy Controls
M. Sosniuk,¹ A. Halpin,^1,2,5,6,7 J. Wizniak,⁷ A. Szkotak,^6,7 S. Urschel,^1,2,5 L. Ionescu,^1,2,5 L. West.^1,2,3,4,5,6
¹Dept of Pediatrics, U of Alberta, Edmonton, Canada; ²Alberta Transplant Institute, Edmonton, Canada; ³Dept of MMI, U of Alberta, Edmonton, Canada; ⁴Dept of Surgery, U of Alberta, Edmonton, Canada; ⁵Canadian National Transplant Research Program, National, Canada; ⁶Dept of Laboratory Medicine, U of Alberta, Edmonton, Canada; ⁷Laboratory Medicine and Pathology, Alberta Health Services, Edmonton, Canada.
INTRODUCTION: Studying pediatric patients includes challenges such as difficulty obtaining samples, limited normal controls and small volumes. Standardized flow cytometry (FC) lymphocyte immunophenotyping panels are…
2018 American Transplant Congress
Hyperglycemia Aggravates Hepatic Ischemia and Reperfusion Injury by Inhibiting Liver Resident Macrophage M2 Polarization via C/EBP-Homologous Protein-Mediated Endoplasmic Reticulum Stress
Z. Rao, J. Sun, X. Pan, Z. Chen, H. Sun, P. Zhang, M. Gao, Z. Ding, C. Liu.
Anesthesiology, First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Background:Aggravated liver ischemia and reperfusion (IR) injury has been observed in hyperglycemic hosts, but its underlying mechanism remains undefined. The aim of the study was…
2018 American Transplant Congress
Significant Difference between Proteasome and Immunoproteasome Inhibition in Acute Kidney Injury
F. Han, C. Ding, Y. Zhao, P. Tian.
Department of Kidney Transplantation, Hospital of Nephropathy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
The proteasome inhibitor bortezomib has successful administrated in kidney transplant recipients with acute or chronic antibody-mediated rejection, but there were some unfavorable cases which arised…
2018 American Transplant Congress
Repeat Kidney Transplant Patients with Active Rejection Have Elevated Donor-Derived Cell-Free DNA
S. Mehta,¹ J. Chang,² T. Hailey,¹ D. Hiller,³ M. Grskovic,³ J. Yee,³ R. Mannon.¹
¹University of Alabama School of Medicine, Birmingham, AL; ²Columbia University Medical Center, New York, NY; ³CareDx, Brisbane, CA.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an established marker of active rejection in de novo kidney transplant recipients. Here we characterize dd-cfDNA in patients who…
2018 American Transplant Congress
Serum Treatment with Fetal Bovine Serum Significantly Increases Luminex-Based HLA Antibody Assay Specificity by Reducing Heterophile Antibody Interference
A. Jaramillo,¹ J. House,¹ L. Nelson,¹ S. Stoll,¹ R. Ridgley,¹ H. Khamash.²
¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ; ²Department of Medicine, Mayo Clinic, Phoenix, AZ.
Mean fluorescence intensity (MFI) values obtained from Luminex-based HLA antibody assays are used to determine the relative strength of HLA antibodies. However, MFI values can…
2018 American Transplant Congress
Temporal Variability of IgG Subclasses
D. Pinelli, M. Gopalakrishnan, A. Joong, P. Thrush, A. Tambur.
Northwestern University, Chicago; Lurie Children's Hospital, Chicago.
The temporal model of IgG subclass switching supports sequential IgG conversion; however, the diversity of previously stimulated B cells is known to shape responses in…
2018 American Transplant Congress
Efficacy of IVIG + Rituximab Desensitization Therapy on HLA Antibodies is Independent of HLA Loci
X. Zhang,¹ S. Jordan.²
¹HLA and Immunogenetics Laboratory, Comprehensive Transplant Center/ Cedars-Sinai Health Systems, Los Angeles, CA; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Aim: Desensitization with the intravenous immunoglobulin (IVIG) and Rituximab therapy is commonly used to promote transplant of highly sensitized patients. It is suggested that HLA-DQ…

« Previous Page
1
…
3
4
5
6
7
…
211
Next Page »